💨 Abstract

Indian generic drugmaker Dr Reddy's Laboratories Q2 profit declined by 9.5% due to one-time charges from a joint venture with Nestle India and Nicotinell acquisition, and an impairment charge due to supply chain constraints in the U.S. The company's total revenue rose 16.5% to 80.38 billion rupees, driven by a 17% increase in revenue from North America.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖